Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults.
Journal article
Costa Clemens SA. et al, (2023), Hum Vaccin Immunother, 19
A Randomized Trial Assessing the Immunogenicity and Reactogenicity of Two Hexavalent Infant Vaccines Concomitantly Administered With Group B Meningococcal Vaccine.
Journal article
Rajan M. et al, (2023), Pediatr Infect Dis J, 42, 66 - 73
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
Journal article
Mentzer AJ. et al, (2023), Nat Med, 29, 147 - 157
Colorectal Endoscopic Stenting Trial (CReST) for obstructing left-sided colorectal cancer: Randomized clinical trial
Journal article
Hill J. et al, (2022), British Journal of Surgery, 109, 1073 - 1080
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females.
Journal article
Marchevsky NG. et al, (2022), EBioMedicine, 81
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Journal article
Li G. et al, (2022), Lancet, 399, 2212 - 2225
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.
Journal article
Ogbe A. et al, (2022), JCI Insight, 7
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
Journal article
Clemens SAC. et al, (2021), Nature Communications, 12
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.
Journal article
Clemens SAC. et al, (2021), Nat Commun, 12
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Journal article
EWER K. et al, (2021), The Lancet
Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222)
Preprint
Flaxman A. et al, (2021)
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm sub-study of a phase 2/3 clinical trial
Journal article
EWER K. et al, (2021), Lancet HIV
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Journal article
Barrett JR. et al, (2021), Nature medicine
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Journal article
Barrett JR. et al, (2021), Nature medicine
Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection
Preprint
Frater J. et al, (2021)
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Journal article
Emary KRW. et al, (2021), Lancet, 397, 1351 - 1362
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Journal article
Voysey M. et al, (2021), Lancet, 397, 881 - 891
Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)
Preprint
Emary KRW. et al, (2021)
Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study.
Journal article
Bach SP. et al, (2021), Lancet Gastroenterol Hepatol, 6, 92 - 105
Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine
Journal article
Voysey M. et al, (2021), The Lancet